silybin/obesity

Lyen an sove nan clipboard la

Chwazi kalite sòt

8 rezilta yo

Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Non-alcoholic fatty liver disease is the most common liver disease worldwide. OBJECTIVE The aim of this study is to compare the metabolic effects of the Mediterranean diet versus the diet associated with silybin, phosphatidylcholine and vitamin E complex in overweight patients with

Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background and purpose: Silymarin, a standardized extract of the milk thistle seeds, has been widely used to treat chronic hepatitis, cirrhosis, and other types of toxic liver damage. Despite increasing studies on the action of silymarin and its major active constituent, silybin in their therapeutic

Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Silybin shows good effects against obesity and metabolic syndrome, but the systemic modulation effect of silybin has not been fully revealed. This study aims to investigate the metabolic regulation by silybin of nonalcoholic fatty liver disease (NAFLD). C57BL/6 J mice were fed a

Changes of gut microbiota during silybin mediated treatment of high-fat diet-induced nonalcoholic fatty liver diseasein mouse.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Gut microbiota involved in pathogenesis of nonalcoholic fatty liver disease (NAFLD). Silybin (Sil), a naturally occurring hepatoprotective agent, was widely used for treating NAFLD. Whether Sil effects gut microbiota during its actions in treating NAFLD, which is unknown. We aimed to

Identification of flavonolignans from Silybum marianum seeds as allosteric protein tyrosine phosphatase 1B inhibitors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Protein tyrosine phosphatase 1B (PTP1B) is an attractive molecular target for anti-diabetes, anti-obesity, and anti-cancer drug development. From the seeds of Silybum marianum, nine flavonolignans, namely, silybins A, B (1, 2), isosilybins A, B (3, 4), silychristins A, B (5, 6), isosilychristin A

Silymarin is an ally against insulin resistance: a review

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Silymarin is obtained from the Milk thistle plant Silybum marianum and has been used over the centuries to treat principally liver disease, although it has also been studied for its beneficial effects in cardioprotection, neuroprotection, immune modulation, and cancer among others. Importantly,

Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Non-alcoholic fatty liver disease (NAFLD) represents the most common and emerging chronic liver disease worldwide. It includes a wide spectrum of liver diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH), which may progress to fibrosis and more severe liver complications

The treatment of NAFLD.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Nonalcoholic fatty liver disease (NAFLD) is becoming an increasing cause of chronic liver damage. The decision of start a medical treatment is based on the documented risk of progression to cirrhosis and liver cancer, when steatohepatitis (NASH) occurs. The therapy of this syndrome requires, as

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye